Sun Pharmaceuticals and Cassiopea SpA have signed licence and supply agreements for Winlevi (clascoterone cream 1%) in the United States (US) and Canada.
Albany Molecular Research, Inc. (AMRI) has been named as the exclusive supplier of the active pharmaceutical ingredient (API) in Cassiopea SpA’s recently approved acne treatment, Winlevi (clascoterone) cream 1%.
Italian speciality pharmaceutical firm Cassiopea has received approval from the US Food and Drug Administration (FDA) for Winlevi (clascoterone cream 1%) as a topical treatment for acne vulgaris.